Last checked at 18 Nov 2015 15:45
18 November 2015
IXICO plc
("IXICO" or the "Company")
Publication of Circular and Notice of General Meeting
18 November 2015: IXICO plc (AIM: IXI), the brain health company, today confirms that further to the announcement made earlier today, a Circular has been published and will be posted to shareholders today in relation to the Proposed Acquisition, Placing, Broker Option, Rule 9 Waiver and Share Restructuring (all of which remain subject to approval by shareholders at a General Meeting to be held on 7 December 2015).
A copy of the Circular will shortly be available on the Company's website at the following URL: http://www.ixico.com/investors/companydocuments.
For further information, please contact:
IXICO plc | Tel: +44 (0) 20 3763 7499 |
Derek Hill, CEO | |
Susan Lowther, CFO | |
Charles Spicer, VP Corporate Development | |
Peel Hunt LLP (Nominated Adviser and Broker) | Tel: +44 (0) 20 7418 8900 |
James Steel | |
Oliver Jackson | |
Sohail Akbar | |
| |
FTI Consulting Limited (Investor Relations) | Tel: +44 (0) 20 3727 1000 |
Simon Conway | |
Mo Noonan | |
Matthew Moss |
Notes to Editors
About IXICO
IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis.
More information is available on www.ixico.com